ABPA syndrome (ABPAs) in CF: FEV1 decline, infectious exacerbations and BMI before and after the year of diagnosis (index year), a case control study Source: International Congress 2014 – Cystic fibrosis: basic science, physiology and clinical aspects Year: 2014
Late Breaking Abstract - Reduction in frequency of pulmonary exacerbations (PE) with inhaled ARD-3150 in non-cystic fibrosis bronchiectasis (NCFB) patients is independent of Pseudomonas aeruginosa (PA) susceptibility at baseline Source: International Congress 2017 – Update on community acquired pneumonia Year: 2017
Microbiological follow-up of patients with non-CF bronchiectasis related to exacerbation frequency, pulmonary function tests (PFT) and HRCT-score Source: Annual Congress 2009 - Exacerbations of COPD and bronchiectasis: aetiology and treatment Year: 2009
Allergic bronchopulmonary aspergillosis (ABPA) prevalence in adult cystic fibrosis (CF) patients. Usefulness of recombinant Aspergillus fumigatus IgE (rAsp f) in diagnosis and monitoring treatment Source: Annual Congress 2012 - Cystic fibrosis (adults and children): new aspects of risk factors, treatments and diagnosis Year: 2012
Accompanying asthma in cystic fibrosis (CF) and non-CF bronchiectatic patients: could we detect it with AMP bronchoprovocation and sputum properties? Source: Eur Respir J 2007; 30: Suppl. 51, 374s Year: 2007
Allergic bronchopulmonary aspergillosis complicating COPD is associated with a higher exacerbation rate and a distinct pattern on chest CT scan compared to COPD Source: International Congress 2016 – Clinical studies in asthma and immunology Year: 2016
Treatment with corticosteroids and yearly decline of forced expiratory flow (FEV1 ) in patients with severe chronic obstructive pulmonary disease (COPD) Source: Annual Congress 2008 - Respiratory structure and function Year: 2008
In active and former smokers with CT detected emphysema but without airway obstruction, the presence of an abnormal DLco is associated with a worse clinical presentation Source: International Congress 2016 – Non-inflammatory COPD monitoring Year: 2016
How to interpret reduced forced expiratory volume in 1 s (FEV1)/vital capacity ratio with normal FEV1 Source: Eur Respir J 2009; 33: 1396-1402 Year: 2009
Long term follow up of the lung function in cystic fibrosis patients with allergic bronchopulmonary aspergillosis (ABPA) Source: Annual Congress 2009 - Cystic fibrosis: understanding a complex disease Year: 2009
Can chronic obstructive lung disease (COPD) criteria be used to manage bronchiectasis (BR) and obliterative bronchiolitis (OB) in children surviving severe lung infection? Source: Eur Respir J 2001; 18: Suppl. 33, 172s Year: 2001
FEV1 decline in patients with chronic obstructive pulmonary disease: Which treatment option is better for slowing of decline? Source: International Congress 2015 – COPD: exacerbations, gas exchange and associated dysfunction Year: 2015
The role of concomitant respiratory diseases on the rate of decline in FEV1 among adult asthmatics Source: Eur Respir J 2003; 21: 95-10 Year: 2003
Effect of prior year pulmonary exacerbation (PE) frequency on response to ARD-3150 in patients with non-cystic fibrosis bronchiectasis (NCFB) chronically infected with Pseudomonas aeruginosa (PA) Source: International Congress 2018 – Improving the quality of life of patients with bronchiectasis Year: 2018
Effect of pulmonary exacerbations on long-term lung function decline in cystic fibrosis Source: Eur Respir J 2012; 40: 61-66 Year: 2012
Frequent exacerbations in COPD are associated with accelerated rate of FEV1 decline Source: Eur Respir J 2006; 28: Suppl. 50, 32s Year: 2006
Changes in the lower airway bacterial community of from adult non-CF bronchiectasis population are significantly associated with exacerbations and the presence of Heamophilus influenza Source: Annual Congress 2012 - Management of severe respiratory infections Year: 2012
Differences in FVC decline by extent of emphysema in patients with combined pulmonary fibrosis and emphysema (CPFE) syndrome Source: International Congress 2015 – New frontiers in the management of interstitial and orphan lung diseases Year: 2015
Changes in total IgE levels predict pulmonary outcome in cystic fibrosis related allergic bronchopulmonary aspergillosis Source: International Congress 2016 – Cystic fibrosis: various aspects Year: 2016
COPD: Plasma surfactant protein-D (SPD) concentration as a predictor of acute exacerbations (AE) probability Source: International Congress 2016 – Features and impact of comorbidities in COPD Year: 2016